And then regarding your obligation to BARDA, if there’s any, can you kind of tell us or highlight for 2023?

Source: https://seekingalpha.com/article/4588032-mediwound-ltd-mdwd-q4-2022-earnings-call-transcript?source=feed_all_articles

BARDA seeks innovations in needle-free vaccine technologies for anthrax, smallpox, and Ebola, focusing on operational improvements and ease of administration, with a consideration for microneedle patches and other needle-free approaches.

Source: https://www.prnewswire.com/news-releases/everglade-consulting-funding-alert-barda-releases-new-broad-agency-announcement-baa-with-updated-areas-of-interest-and-additional-funding-opportunities-301940913.html

But more importantly, with our C1 protein production platform, with the presentation there was about 400 plus people on the call with the FDA and BARDA, and we're getting a lot of inbound excitement about where we are as people are seeing.

Source: https://seekingalpha.com/article/4602868-dyadic-international-inc-dyai-q1-2023-earnings-call-transcript?source=feed_all_articles